CONCORD, Calif.--(BUSINESS WIRE)--Cerus Corporation (NASDAQ: CERS) announced results from 10 studies on the INTERCEPT Blood System, presented this week at the AABB annual meeting in Montreal, Canada. Study outcomes highlighted the application of the INTERCEPT Blood System for inactivation of harmful bacteria in the blood supply in place of standard bacterial screening methods and meeting certain international accreditation standards required by the AABB. Studies also highlighted data from the INTERCEPT red blood cell program showing inactivation of a broad range of pathogens while maintaining proper hydration and functionality of red cells treated with INTERCEPT.
